LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer

New Data at ESMO 2021 Support Initiation of Phase 3 Trial of LUMAKRAS Plus Vectibix in Patients With 3L+ Colorectal Cancer Amgen is Leading the Largest and Most Comprehensive Development Program in Patients with the KRAS G12C Mutation THOUSAND OAKS, ... Biopharmaceuticals, Oncology Amgen, LUMAKRAS, Vectibix, sotorasib, panitumumab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news